Amyris cancels auction for its Lab-to-Market assets

By Sarah Lizee

Olympia, Wash., Jan. 18 – Amyris, Inc. canceled an auction that was scheduled for Friday for its Lab-to-Market assets, according to a notice filed with the U.S. Bankruptcy Court for the District of Delaware.

The company said it did not receive any qualifying bids for the assets.

A minimum reserve price for the assets had been set at $255.84 million. The amount consists of $197.64 million due under the company’s debtor-in-possession facility and a $58.2 million plan effective date funding schedule.

Intrepid Investment Bankers LLC acted as investment banker.

Emeryville, Calif.-based Amyris is a synthetic biotechnology company. The company filed bankruptcy on Aug. 9 under Chapter 11 case number 23-11131.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.